TREMBLAY GILLES BERNARD,VIAU ELISABETH,FILION MARIO
申请号：
NZ62674213
公开号：
NZ626742A
申请日:
2013.02.22
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Discloses a pharmaceutical combination comprising an anti-clusterin antibody or an antigen binding fragment thereof capable of inhibiting epithelial to mesenchymal transition and an EGFR inhibitor, wherein the EGFR inhibitor is an EGFR tyrosine kinase inhibitor selected from the group consisting of gefitinib, erlotinib, imatinib, lapatinib and semazinib or an anti-EGFR antibody or antigen binding fragment thereof. Further discloses related kits and methods of treating cancer.
